Dermata Therapeutics Inc (DRMA)

Currency in USD
0.7061
+0.0032(+0.46%)
Closed·
After Hours
0.7099+0.0038(+0.54%)
·
DRMA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
0.69000.7330
52 wk Range
0.57393.7900
Key Statistics
Prev. Close
0.7061
Open
0.73
Day's Range
0.69-0.733
52 wk Range
0.5739-3.79
Volume
255.67K
Average Volume (3m)
127.83K
1-Year Change
-63.22%
Book Value / Share
1.34
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DRMA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.0000
Upside
+324.87%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Dermata Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Dermata Therapeutics Inc Company Profile

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance’s botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Compare DRMA to Peers and Sector

Metrics to compare
DRMA
Peers
Sector
Relationship
P/E Ratio
−0.4x−4.5x−0.5x
PEG Ratio
0.000.020.00
Price/Book
0.6x3.1x2.6x
Price / LTM Sales
-192.5x3.2x
Upside (Analyst Target)
334.5%167.9%42.0%
Fair Value Upside
Unlock8.1%6.6%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3.0000
(+324.87% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.45 / -1.16
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

DRMA Income Statement

People Also Watch

0.606
ADIL
-3.81%
2.15
BMGL
-4.02%
0.2196
PCSA
-5.14%
2.4800
DARE
-2.75%
7.150
CVM
-16.96%

FAQ

What Stock Exchange Does Dermata Therapeutics Trade On?

Dermata Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Dermata Therapeutics?

The stock symbol for Dermata Therapeutics is "DRMA."

What Is the Dermata Therapeutics Market Cap?

As of today, Dermata Therapeutics market cap is 4.50M.

What Is Dermata Therapeutics's Earnings Per Share (TTM)?

The Dermata Therapeutics EPS (TTM) is -4.23.

From a Technical Analysis Perspective, Is DRMA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Dermata Therapeutics Stock Split?

Dermata Therapeutics has split 2 times.

How Many Employees Does Dermata Therapeutics Have?

Dermata Therapeutics has 8 employees.

What is the current trading status of Dermata Therapeutics (DRMA)?

As of 30 Jul 2025, Dermata Therapeutics (DRMA) is trading at a price of 0.71, with a previous close of 0.71. The stock has fluctuated within a day range of 0.69 to 0.73, while its 52-week range spans from 0.57 to 3.79.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.